Market Overview

As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy

Related GSK
Pharmaceutical Earnings: Pfizer And Merck Are Slated To Report Tuesday Morning
Earnings Scheduled For April 25, 2018
Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead (Seeking Alpha)

The Vetr crowd on Thursday upgraded its rating for GlaxoSmithKline plc (ADR) (NYSE: GSK) from 3 stars (Hold), issued 527 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Share price in GSK took a pronounced downturn throughout April, in part due to the company's recall of 600,000 defective inhalers that occasionally failed in delivering the correct amount of medication per use.

GSK's stock has fallen more than 2.5 percent since the beginning of the month and was recently trading around $40.80.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for GlaxoSmithKline is up at $45.30, which is still just below the average analyst target price of $45.67. Less than 2 percent of Vetr users are holding GSK in their watch lists.

Latest Ratings for GSK

Oct 2017Bank of AmericaDowngradesBuyNeutral
Jul 2017CitigroupDowngradesBuyNeutral
Sep 2016PiperJaffrayInitiates Coverage onOverweight

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings General


Related Articles (GSK)

View Comments and Join the Discussion!